

TABLE OF CONTENTS

August 31, 2009

No. 2153

BUSINESS

- 1 DSP to Transform Itself into Global Research-Driven Pharma: President Tada
 - Two More Candidates of Global Strategic Products in Pipeline
 - Marketing Strategies to Be Built Up Based on MRs' Proposals
 - In-House MR Certification System to Upgrade Quality of Detailing in CV Field
- 3 Kowa Licenses Livalo to MTPC in Taiwan, Indonesia
- 3 Makers' FY2009 1st Qtr Business Roundup
- 6 Cravit Ranked No. 1 on Both HP and GP Markets: Rep Track Survey
- 8 **BUSINESS NEWS IN BRIEF**
 - Hisamitsu Completes Tender Offer for Noven Pharm.
 - Schering-Plough Aims at 10% Market Share for Remeron
 - Chugai to Increase Number of Cancer-Specialized MRs to 550
 - Daiichi Sankyo to Create Vaccine Business Planning Department
 - Site Support Institute Starts Contract PI Trials
 - Mediscience to Acquire CPOC
 - Daiichi Sankyo Wins Patent Litigation over Olmesartan against Mylan
 - Shionogi Sues Sawai for Infringement of Flomox Crystal Patent
- 9 **TOPICS**
 - Levemir Does Not Increase Cancer Risk: Novo Nordisk

GENERIC

- 10 Leading Generic Houses Post Strong Growth in Both Sales, Profits
- 10 Sampling Tests Show Problems with Only 2 of 876 Products
 - Approval Conditions Not Met by 8 Products
- 11 *Koroshō* to Promote Sharing of Know-how to Promote Use of Generics

REGULATORY

- 12 Japan, China, South Korea Start Working-Level Regulatory Consultations
- 12 Everolimus Approved in EU: Novartis
- 13 **REGULATORY NEWS IN BRIEF**
 - FDA Extends Review Time for Prevnar 13 by 90 Days
 - NovoRapid 70 Mix Approved
 - New Indication, Formulations Approved for Elplat
 - Avastin + Docetaxel Therapy Approved for Breast Cancer in the EU
 - FDA Advisory Committee Recommends Approval of Prolia: Amgen
 - FDA Warns Over Pediatric Cancer Risk with TNF Blockers

- *Koroshō* to Require No Change in Labeling on TNF Blockers
- JPMA's Unapproved Drugs Development Support Center Selected as Fund Management Organization

R&D

14 R&D NEWS IN BRIEF

- CS-8958 Shown to Be Non-Inferior to Tamiflu in PIII
- Anti-MRSA Agent WAP-8294A2 to Be Funded by NEDO: aRigen
- SyB-0702 to Be Funded by NEDO: Symbio
- p53 Inhibits iPS Cell Formation

SELF-MEDICATION

- 16 SSP to Place Top Priority on Operating Profit Rate
- 16 G&G to Develop Overseas Business in Earnest
- 17 **SELF-MEDICATION NEWS IN BRIEF**
 - Rohto: Sales Up 11.2% with Large Increases in Profits
 - JPA to Survey Changes in Sales of OTC Drugs
 - OTC Drug Market to Reach ¥627.7 Bil. in 2009: Fuji-Keizai
- 17 **Statistics**
 - Sales of Ethical Drugs Up 7.9% in June: Crecon

MEDICAL FACILITIES & NURSING CARE

- 18 GSK Starts Adjusting Shipments of Relenza due to Rush of Orders
- 18 Full-Scale Flu Epidemic May Have Begun: Health Minister
 - Reports of Flu Patients Rapidly Increasing: NIID
 - High-Risk Patients, Healthcare Providers Should Be Preferentially Vaccinated
- 19 *Koroshō* to Prepare GL for Clinical Assessment of Antidepressants
- 20 *Koroshō* to Start Japanese Version of Sentinel Initiative
 - Need for Large Databases Stressed at 1st Council Meeting
- 22 Allopurinol + Uralyt Combination Useful for Management of MetS
 - Adiponectin Shows Strong Correlation with MetS Morbidity
- 22 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
 - Warnings Added for Champix
 - *Koroshō* to Revise Admission System for Mentally-Ill Patients
 - Gene KCNQ1 Causes Diabetes in Many Japanese: Prof. Kadowaki
- 23 **TOPICS**
 - CSL Behring Sponsors HAE Study Meetings for Doctors